Creative Biolabs develops strategies to support PROTAC-based drug discovery, providing one-stop services for PROTAC molecule discovery and validation, as well as research reagents.
New York, United States - November 1, 2022 /MarketersMEDIA/ —
Since protein degradation therapy gained a seat in modern therapeutics in the past decade, Creative Biolabs has been exploring PROTAC—one of the most potent approaches showing great promise in resolving disease-causing proteins recognized as hard-to-target previously, providing custom solutions to support PROTAC discovery, PROTAC optimization, and characterization.
"We've been working on PROTAC discovery for years," according to a specialist, "and established a one-stop pipeline encapsulating the entire process for PROTAC development, aiming to fast track our clients' projects."
The workflow initiates with ligand design for the target protein when both available ligand products and tailor-made development of the ligand for the protein of interest can be adopted. Then scientists at Creative Biolabs proceed to determine the ligand for E3 ligase that is meant for tagging the disease-causing protein for ubiquitination and degradation.
"The next decisive factor is a suitable linker," added the specialist, "and we can do further PROTAC linker design to maximize the efficiency for downstream ubiquitination and degradation of the pathogenic protein."
Following structural modification and peptide and compound synthesis, Creative Biolabs will handle the comprehensive evaluation of candidate molecules through in vitro assays to determine their potency covering solubility, chemical stability, cell permeability, and binary target engagement, as well as in vivo assays to assess toxicity, absorption, distribution, metabolism, and excretion.
"Only after a molecule has been verified both in terms of potency and safety will it be worthwhile moving on to the next stage," added the specialist. "Therefore, we've included a full set of validation assays with the aim to characterize core factors that may shape its efficacy, like PROTAC cell permeability, which critically determines the potential application of a PROTAC molecule."
Creative Biolabs has prepared necessary reagents which can immediately join the ongoing PROTAC projects, including linkers, ligands, E3 ligases, and target proteins.
"PROTAC has attained a place in recent years," commented the specialist, "yet efforts still need to be made in this therapeutic field as there are not many available options. We can be the one to expedite the process."
Learn more about Creative Biolabs' PROTAC solutions at https://www.creative-biolabs.com/protac/.
About
Creative Biolabs is a CRO working dedicatedly in the biotechnology field, providing customized solutions to support global researchers' programs involving new drug discovery and disease research. 2022 marked Creative Biolabs a year full of events and networking opportunities, with a group of scientific delegates showing faces in several in-person conferences presenting capabilities, and breeding new partnerships. Last but not least, during the fourth season of 2022, Creative Biolabs will showcase at the Antibody Engineering & Therapeutics US 2022 conference!
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/protac/
Release ID: 89084100
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.
